A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules - Concepedia

Concepedia

Publication | Open Access

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

DOI Full Paper Access

58

Citations

39

References

2019

Year

Margaret E. Gatti‐Mays, Julius Strauss, Renee N. Donahue, Claudia Palena, Jaydira Del Rivero, Jason M. Redman, Ravi A. Madan, Jennifer L. Marté, Lisa M. Cordes, Elizabeth Lamping,

Clinical Cancer Research

Abstract

The BN-CV301 vaccine can be safely administered to patients with advanced cancer. Further studies of the vaccine in combination with other agents are planned.<i>See related commentary by Repáraz et al., p. 4871</i>.

References

	Year	Citations

Page 1